107 related articles for article (PubMed ID: 38734687)
1. The role of clock genes and circadian rhythm in the development of cardiovascular diseases.
Takeda N; Maemura K
Cell Mol Life Sci; 2015 Sep; 72(17):3225-34. PubMed ID: 25972277
[TBL] [Abstract][Full Text] [Related]
2. Pressure Building Against the Clock: The Impact of Circadian Misalignment on Blood Pressure.
Shafer BM; Kogan SA; McHill AW
Curr Hypertens Rep; 2024 Jan; 26(1):31-42. PubMed ID: 37837518
[TBL] [Abstract][Full Text] [Related]
3. Circadian-Regulated GR Signaling Mediates Morning Arrhythmias.
Rabinovich-Nikitin I; Crandall M; Kirshenbaum LA
Circ Res; 2024 May; 134(10):1327-1329. PubMed ID: 38723035
[No Abstract] [Full Text] [Related]
4. Stimulation of soluble guanylyl cyclase (sGC) by riociguat attenuates heart failure and pathological cardiac remodelling.
Rüdebusch J; Benkner A; Nath N; Fleuch L; Kaderali L; Grube K; Klingel K; Eckstein G; Meitinger T; Fielitz J; Felix SB
Br J Pharmacol; 2022 Jun; 179(11):2430-2442. PubMed ID: 33247945
[TBL] [Abstract][Full Text] [Related]
5. Chronic circadian rhythm disorder induces heart failure with preserved ejection fraction-like phenotype through the Clock-sGC-cGMP-PKG1 signaling pathway.
Che Y; Shimizu Y; Hayashi T; Suzuki J; Pu Z; Tsuzuki K; Narita S; Shibata R; Murohara T
Sci Rep; 2024 May; 14(1):10777. PubMed ID: 38734687
[TBL] [Abstract][Full Text] [Related]
6. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
Breitenstein S; Roessig L; Sandner P; Lewis KS
Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
[TBL] [Abstract][Full Text] [Related]
7. Zhenwu decoction ameliorates cardiac hypertrophy through activating sGC (soluble guanylate cyclase) - cGMP (cyclic guanosine monophosphate) - PKG (protein kinase G) pathway.
Chen L; Zhou X; Deng Y; Yang Y; Chen X; Chen Q; Liu Y; Fu X; Kwan HY; You Y; Jin W; Zhao X
J Ethnopharmacol; 2023 Jan; 300():115705. PubMed ID: 36099983
[TBL] [Abstract][Full Text] [Related]
8. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice.
Xue M; Li T; Wang Y; Chang Y; Cheng Y; Lu Y; Liu X; Xu L; Li X; Yu X; Sun B; Chen L
Clin Sci (Lond); 2019 Aug; 133(15):1705-1720. PubMed ID: 31337673
[TBL] [Abstract][Full Text] [Related]
10. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
[TBL] [Abstract][Full Text] [Related]
11. The Circadian Biology of Heart Failure.
El Jamal N; Lordan R; Teegarden SL; Grosser T; FitzGerald G
Circ Res; 2023 Jan; 132(2):223-237. PubMed ID: 36656971
[TBL] [Abstract][Full Text] [Related]
12. Hydrogen Sulfide Attenuates Lymphedema Via the Induction of Lymphangiogenesis Through a PI3K/Akt-Dependent Mechanism.
Suzuki J; Shimizu Y; Hayashi T; Che Y; Pu Z; Tsuzuki K; Narita S; Shibata R; Ishii I; Calvert JW; Murohara T
J Am Heart Assoc; 2022 Nov; 11(21):e026889. PubMed ID: 36285798
[TBL] [Abstract][Full Text] [Related]
13. Direct reprogramming of adult adipose-derived regenerative cells toward cardiomyocytes using six transcriptional factors.
Narita S; Unno K; Kato K; Okuno Y; Sato Y; Tsumura Y; Fujikawa Y; Shimizu Y; Hayashida R; Kondo K; Shibata R; Murohara T
iScience; 2022 Jul; 25(7):104651. PubMed ID: 35811849
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic angiogenesis for patients with no-option critical limb ischemia by adipose-derived regenerative cells: TACT-ADRC multicenter trial.
Shimizu Y; Kondo K; Hayashida R; Sasaki KI; Ohtsuka M; Fukumoto Y; Takashima S; Inoue O; Usui S; Takamura M; Sakuma M; Inoue T; Nagata T; Akashi YJ; Yamada Y; Kato T; Kuwahara K; Tateno K; Kobayashi Y; Shibata R; Murohara T;
Angiogenesis; 2022 Nov; 25(4):535-546. PubMed ID: 35802311
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
